Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2021

Tanimoto Azusa, Matsumoto Shingo, Takeuchi Shinji, Arai Sachiko, Fukuda Koji, Nishiyama Akihiro, Yoh Kiyotaka, Ikeda Takaya, Furuya Naoki, Nishino Kazumi, Ohe Yuichiro, Goto Koichi, Yano Seiji

Abstract excerpt

PURPOSE: In ALK-rearranged non-small cell lung cancer (NSCLC), impacts of concomitant genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are not yet well understood. Here, we investigated genetic alterations related to ALK-TKI resistance using clinico-genomic data and explored effective therapies to overcome the resistance in preclinical models through the identification of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Boron Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbazoles

Share to Crizotinib

Share to Mice, SCID

Share to Piperidines

Share to Proteasome Endopeptidase Complex

Share to Proto-Oncogene Proteins c-bcl-2

Source

Identifiers

PMID: 33310890
DOI: 10.1158/1078-0432.CCR-20-2853

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.PMID 33310890Read ↗

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinibSemantic proximity Read ↗

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancerSemantic proximity Read ↗

Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial ApoptosisSemantic proximity Read ↗

Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.Semantic proximity Read ↗

Targeting BCL‐2 family proteins to overcome drug resistance in non‐small cell lung cancerSemantic proximity Read ↗

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer.Semantic proximity Read ↗

Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.Semantic proximity Read ↗

Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors.Semantic proximity Read ↗

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.Semantic proximity Read ↗

The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.Semantic proximity Read ↗

Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells.Semantic proximity Read ↗

Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.